Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 445-450

  Wang, Fen ^a   Elliott, Robert L ^a   Head, Jonathan F ^a  

^a The Mastology Research Institute   (United States)

Author keywords

Deferoxamine; Iron; Mammary neoplasms; Rats

Indexed keywords

DEFEROXAMINE MESYLATE; IRON CHELATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HEMATOCRIT; INTRAVENOUS DRUG ADMINISTRATION; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON INTAKE; IRON METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME; WEIGHT GAIN;

ADENOCARCINOMA; ANIMALS; BODY WEIGHT; DEFEROXAMINE; FEMALE; HEMATOCRIT; IRON, DIETARY; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED;

EID: 0032922739     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Wrigglesworth JM and Baum H: The biochemical functions of iron. In: Iron in biochemistry and medicine (Jacobs A and Worwood M. eds.). London, Academic Press, 1980, Vol. 2, pp 29-86.
2. Reichard P and Ehrenberg A: Ribonucleotide reductase: A radical enzyme. Science 221: 514-519, 1993.
3. Vezzoni P, Levi S, Gabri E, Pozzi MR, Spinazze S and Arosio P: Ferritin in malignant and non-malignant lymphoid cells. Br J Haematol 62: 105-110, 1986.
4. Weinstein RE, Bond BH and Silberberg BK: Tissue ferritin concentration in carcinoma of the breast. Cancer 50: 2406-2409, 1982.
5. Sherman N, Kupfer B and Moroz C: Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiology 59: 19-25, 1991.
6. Weinstein RE, Bond BH and Silberberg BK: Tissue ferritin concentration and prognosis in carcinoma of the breast. Breast Cancer Res and Treatment 14: 349-353, 1989.
7. Elliott RL, Elliott MC, Wang F and Head JF: Breast carcinoma and the role of iron metabolism. N Y Academy of Sciences 698: 159-166, 1993.
8. Goldberg L, Martin LE and Smith JP: Iron overloading phenomena in animals. Toxicol Appl Pharmacol 2: 683-707, 1960.
9. Hann H-WL, Stahlhut MW and Menduke H: Iron enhances tumor growth. Cancer 68: 2407-2410, 1991.
10. Foster BJ, Clagett-Carr K, Hoth D and Leyland-Jones B: Gallium nitrate: the second metal with clinical activity. Cancer Treat Rep 70: 1311-1319, 1986.
11. Estrov Z, Tawa A, Wang XH, Dube ID, Sulh H, Cohen A, Gelfand EW and Freedman M H: In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 69: 757-761, 1987.
12. Kemp JD, Smith KM, Kanner LJ, Gomez F, Thorson JA and Naumann PW: Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and the immunoglobulin G monoclonal antibody against the transferrin receptor. Blood 76: 991-995, 1990.
13. Keberle H: The biochemistry of deferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 119: 758, 1964.
14. Richardson D, Ponka P and Baker E: The Effect of iron (III) chelator, deferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 54: 685-689, 1994.
15. Becton DL and Roberts B: Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. Cancer Res 49: 4809-4812, 1989.
16. Becton DL and Bryles P: Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 48: 7189-7192, 1988.
17. Hann H-WL, Stahlhut MW and Hann C: Effect of iron and deferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 11: 566-569, 1990.
18. Hann H-WL, Stahlhut MW and Menduke H: Iron enhances tumor growth. Cancer 68: 2407-2410, 1991.
19. Hann H-WL, Stahlhut MW and Blumberg BS: Iron nutrition and tumor growth: Decreased tumor growth in iron-deficient mice. Cancer Res 48: 4168-4170, 1988.
20. Hann H-WL, Stahlhut MW, Rubin R and Maddrey WC: Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in thymic mice. Cancer 70: 2051-2056, 1992.
21. Siegers CP, Bumann D, Baretton G and Younes M: Dietary iron enhances the tumor rate in dimethylhydrazine induced colon carcinogenesis in mice. Cancer Letter 41: 251-256, 1988.
22. Head JF and Elliott RL: Inhibition of cell growth in mammary carcinoma cell lines by deferoxamine mesylate. Breast Cancer Res Treat 19: 209, 1991.
23. Head JF, Bruce TL and Elliott RL: Inhibitory effect of deferoxamine mesylate in the growth of HeLa and MCF-7 carcinoma cell lines. Proc Amer Assoc Cancer Res 33: 505, 1992.
24. Greengard O and Head JF: Common characteristics of normal and cancerous growth in vivo. Advan Enzyme Regul 32: 211-224, 1992.
25. Renton FJ and Jeitner TM: Cell cycle-dependent inhibition of the proliferation of human neutral tumor cell line by iron chelator. Biochem Pharmacol 51: 1553-1561, 1996.
26. ∼ deprivation results in an increase in p53 expression. Bio Chem Hoppe Seyler 376: 627-630, 1995.
27. Hileti D, Panayiotidis P and Hoffbrand AV: Iron chelator induce apoptosis in proliferating cells. Br J Heamatol 89: 181-187, 1995.
28. Haq RU, Wereley JP and Chitambar CR: Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol 1428-432, 1995.
29. Kovar J, Seligman P and Gelfand EW: Inhibition of growth of the lymphocyte lines by deferoxamine under various iron-supply conditions. Folia Biol (Praha) 39: 29-39, 1993.
30. Voest EE, Rooth H, Neijt JP, Van Asbeck BS and Marx JJ: The In v o response of human tumor cells to desferrioxamine in growth medium dependent. Cell Prolif 26: 77-88, 1993.
31. Bomford A, Isaac J, Roberts S, Edwards A, Young S and Williams R: The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukaemic cells. Biochem J 236: 243-249, 1986.
32. Wang F, Head JF and Elliott RL: The up regulation of transferrin receptors by deferoxamine enhances the growth inhibitory effect of gallium-transferrin on MCF-7 cells. Pro Am Assoc Cancer Res 37: A2423, 1996.
33. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA and Helson L: Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 50: 4929-4930, 1990.
34. Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, Desio L. Fidani P, Amici A and Helson L: Deferoxamine, cyclophosphamide, etoposide, carboplatin and thiotepa (D-CECaT): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 15: 319-322, 1992.
35. Head JF, Nutt DR, Elliott MC, Wang F and Elliott RL: Phase I/II study of sequentially administered deferoxamine, cisplatin-transferrin complex and FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in advanced breast cancer. Proc Am Asso Cancer Res 35: A1353, 1994.
36. Head JF, Wang F and Elliott RL: Antineoplastic drugs that interfere with iron metabolism in cancer cells. Advan Enzyme Regul 37: 147-169, 1997.